Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Editas Medicine (EDIT) over the last 11 years, with Q2 2025 value amounting to -$1.2 million.

  • Editas Medicine's Gains from Investment Securities fell 101238.1% to -$1.2 million in Q2 2025 from the same period last year, while for Sep 2025 it was -$2.3 million, marking a year-over-year decrease of 23976.43%. This contributed to the annual value of -$3.4 million for FY2024, which is 20092.95% down from last year.
  • Editas Medicine's Gains from Investment Securities amounted to -$1.2 million in Q2 2025, which was down 101238.1% from -$1.0 million recorded in Q1 2025.
  • Editas Medicine's 5-year Gains from Investment Securities high stood at $19.8 million for Q4 2022, and its period low was -$4.1 million during Q3 2024.
  • Over the past 5 years, Editas Medicine's median Gains from Investment Securities value was $505000.0 (recorded in 2022), while the average stood at $2.2 million.
  • In the last 5 years, Editas Medicine's Gains from Investment Securities surged by 191800.61% in 2022 and then tumbled by 101238.1% in 2025.
  • Quarter analysis of 5 years shows Editas Medicine's Gains from Investment Securities stood at $983000.0 in 2021, then soared by 1918.01% to $19.8 million in 2022, then crashed by 75.21% to $4.9 million in 2023, then plummeted by 101.22% to -$60000.0 in 2024, then plummeted by 1846.67% to -$1.2 million in 2025.
  • Its Gains from Investment Securities stands at -$1.2 million for Q2 2025, versus -$1.0 million for Q1 2025 and -$60000.0 for Q4 2024.